ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The vaccine is under FDA review
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Silo enters into commercial evaluation license agreement for next generation liposomes
Subscribe To Our Newsletter & Stay Updated